Description
SBI-115 is a potent TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5.
SBI-115 is a potent TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5.
Alternate Name/Synonyms: 4-Pyrimidinecarboxylic acid, 5-chloro-2-(ethylsulfonyl)-, 3-methylphenyl ester; SBI115
Appearance: Crystalline solid
Formulation:
CAS Number: 882366-16-7
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₄H₁₃ClN₂O₄S
Molecular Weight: 340.78
Cell-Permeable?: True
Purity: ≥98% by HPLC
Solubilities: >50 mg/ml in DMSO
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: A TGR5 (GPCR19) antagonist
MDL Number:
PubChem CID: 18879973
SMILES: CCS(=O)(=O)C1=NC=C(C(=N1)C(=O)OC2=CC=CC(=C2)C)Cl
InChi: InChI=1S/C14H13ClN2O4S/c1-3-22(19,20)14-16-8-11(15)12(17-14)13(18)21-10-6-4-5-9(2)7-10/h4-8H,3H2,1-2H3
InChi Key: IJPXOPBVXVPPEW-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20ºC |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |